The DOI matches its Crossref record; 322 of the 322 references it cites were found in a registry or an index.
Viral vector platforms within the gene therapy landscape
Open accessAbstract
Throughout its 40-year history, the field of gene therapy has been marked by many transitions. It has seen great strides in combating human disease, has given hope to patients and families with limited treatment options, but has also been subject to many setbacks. Treatment of patients with this class of investigational drugs has resulted in severe adverse effects and, even in rare cases, death. At the heart of this dichotomous field are the viral-based vectors, the delivery vehicles that have allowed researchers and clinicians to develop powerful drug platforms, and have radically changed the face of medicine. Within the past 5 years, the gene therapy field has seen a wave of drugs based on viral vectors that have gained regulatory approval that come in a variety of designs and purposes. These modalities range from vector-based cancer therapies, to treating monogenic diseases with life-altering outcomes. At present, the three key vector strategies are based on adenoviruses, adeno-associated viruses, and lentiviruses. They have led the way in preclinical and clinical successes in the past two decades. However, despite these successes, many challenges still limit these approaches from attaining their full potential. To review the viral vector-based gene therapy landscape, we focus on these three highly regarded vector platforms and describe mechanisms of action and their roles in treating human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent developments use dual/multiple vector strategy29,67 that bypasses the 4.7 kb maximum size restriction for AAVs utilizing inteins and exteins to join multiple peptide products into the large functional protein in the host cells.68–72”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The use of recombinant or engineered vector capsids can further increase tissue-specific targeting by allowing more precise control over the various elements in a capsid, and vector modifications. Selection of cell-type-specific promoters, further refines targeting to the affected cell types.29,111”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“Although viral vectors are a promising approach to deliver gene editing technology to the CNS, viral delivery platforms can be limited by pre-existing viral immunity, transgene size constraints, undesired vector integration, and adverse events related to the viral vector (10–12).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [11]
In the citing paper
“These viruses show good safety when administered to target tissues, do not integrate in the recipient genome, successfully transduce retinal cells, and can carry genes of around 30 kb long.4,29,54–56”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [29]
In the citing paper
“However, these vectors tend to be rapidly cleared due to the presence of neutralizing antibodies from pre-existing immunity.4,29,54–56”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [29]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Research works printed but not linked: 7
- Fields, B. N., Knipe, D. M. & Howley, P. M. Fields’ Virology (Wolters Kluwer, 2007).
- Wold, W. S. M. & Ison MG. In Fields Virology (eds. Knipe, D. M. & Howley, P. M.) 6th edn, 1732–1767 (Lippincott, 2013).
- Packiam, V. T. et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results. Urol. Oncol. 36, 440–447 (2018). · DOI · Paper page
- Chan, Y. K. et al. Reducing AAV-mediated immune responses and pathology in a subretinal pig model by engineering the vector genome. ASGCT 23rd Annu. Meet. 27, 298–298 (2020).
- Kiss, S., Osborne, A., Hoang, C. & Turpcu, A. In American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting 2020 Vol. 28, 220–221 (Molecular Therapy, 2020).
- Pfizer, Inc. Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD), https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd (2019).
- Hordeaux, J. et al. Method to prevent AAV-induced dorsal root ganglia toxicity & axonopathy in nonhuman primates, and insights into the pathophysiology. ASGCT 23rd Annu. Meet. 28, 214–215 (2020).
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationMendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Gupta, D., Zickler, A. M., & El Andaloussi, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113961 · Cited by 418
Metadata
- Authors
- Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Sichuan University (CN)
- Corresponding author
- Tai, Phillip W. L.
- Gao, Guangping
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-02-08
- Volume
- 6
- Issue
- 1
- Pages
- 53-53
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC7868676
- OpenAlex
- W3128825549
- Cited by
- 1,404
- References
- 321
- Citations by year
- 2026: 226 · 2025: 323 · 2024: 359 · 2023: 273 · 2022: 162 · 2021: 60
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS076991-01)
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1P01AI100263-01)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (4P01HL131471-02, UG3 HL147367-01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- viral vectors, gene therapy, adenoviral vector, adeno-associated virus vectors, lentiviral vectors, monogenic disorders, regulatory approval, mechanism of action
- MeSH terms
- Dependovirus, Genetic Vectors, Humans, Genetic Therapy, Lentivirus, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral vector platforms within the gene therapy landscape. https://app.cochat.ai/papers/10.1038/s41392-021-00487-6
- The paper
- Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021). Viral vector platforms within the gene therapy landscape. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-021-00487-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.